Moreover, therapies involving cytokines that enhance the activation and multiplication of immune cells, including interleukin-2 (IL-2) and interleukin-12 (IL-12), are currently under investigation for their potential to trigger immune responses in bone cancer. This evidence concerns the gene IL2 and bone cancer.